Hot melt extrusion (HME) is the process of using heat and presser for melting polymer and continuously forcing the material through an orifice. HME process has been developed for producing polymer products with uniform shape and density and has been used in industrial application since the 1930s. Recently, HME technology has been brought in use in pharmaceutical application where it is dominantly used for manufacturing APIs with polymers to augment bioavailability or prepare precursors for thermoplastic drug eluting devices.
Control valves are regarded among the most integral parts of various manufacturing and process industries. Features such as effective flow rate control and consequential control of process quantities such as temperature, pressure and fluid level make them highly essential for carrying industrial processes seamlessly.
Xanthan gum is a complex exopolysaccharide, it is a polymer composed of sugar residues, secreted by a microorganism into the surrounding environment. Xanthan gum is widely used as a thickening and stabilizing agent in a wide variety of food & beverages and industrial products. Some of the common uses of xanthan gum finds in Cosmetics, Baked goods and pastry fillings, Ice cream and sherbet, Industrial uses, Jams, jellies and sauces, Lotions, Medicines, Pudding, Salad dressings, Toothpastes, Yogurt, etc. In oilfield applications xanthan gum provides excellent rheological control for water-based drilling, completion and work-over fluids in a wide range of brines.
Nuclear medicine/ radiopharmaceuticals are agents used to diagnose certain medical problems or treat certain diseases condition. Increasing awareness of radiopharmaceuticals, growing number of pharmaceutical companies and rising research institutes are major factors that assisting the growth of nuclear medicine/ radiopharmaceuticals market globally.
The beta glucan is considered as an important functional ingredient with numerous health benefits. The industries are adopting beta-glucan to fortify foodstuff with high dietary fibres as consumer interests in the nutraceutical products is on escalation. Furthermore beta-glucan actively impacts the metabolic parameters and help curing the chronic diseases.
The biological safety testing market is set to reach US$ 8,935.4 Mn by 2026 from US$ 3,120.8 Mn in 2017 growing at an impressive pace with a compounded annual growth rate (CAGR) of 12.5% during the forecast period from 2018 to 2026. The primary features responsible for the biological safety testing market are rising prevalence of chronic diseases and rapid growth in the clinical laboratories worldwide.
Rabies is a fatal neurological disease, usually spread to humans through the bite of a rabid animal, and it is a persistent global problem. Factors such growing treatment awareness and rising initiatives of government organizations in prevention of rabies are primarily driving the growth of human rabies treatment market globally.
Acute renal failure is a rapid onset of renal function impairment which is potentially reversible depending on the cause and the extent of being untreated. Acute renal failure is a common condition experienced during critical illness and ICU admission.
Industrial gases are gaseous materials that are manufactured for use in the industry. The principal industrial gases available are oxygen, nitrogen, helium, acetylene, argon, hydrogen, carbon dioxide and others (krypton, xenon, methane, carbon monoxide, etc.).
Gout is a complex form of inflammatory arthritis characterized by recurrent attacks of a severe pain and swollen joints. Gout therapeutics market is rapidly growing due to factors such as growing incidence of gout, significant unmet needs, growing treatment awareness, and promising pipeline molecules. The incidence of gout varies widely around the globe, with developed countries generally having higher prevalence than developing countries due to genetic, dietary and environmental factors.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.